Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.
Official title: Clinical Study on the Effect of Routine Treatment and Intensive Treatment on the Regulation of Graves' Disease and the Cumulative Recurrence Two Years After Drug Withdrawal
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2018-05-01
Completion Date
2030-07-31
Last Updated
2023-12-11
Healthy Volunteers
No
Interventions
Methimazole
Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
Locations (1)
the First Affiliated Hospital of Nanjing Medical University
Nanjing, China